Targeting BIRC5/survivin as a therapeutic strategy for cancer treatment has become increasingly attractive, as summarized in Table 1, because of its upregulation in both gliomas and breast cancer and its essential role in inhibiting cell death. This evidence concerns the gene BIRC5 and breast carcinoma.